Advancing ALS Drug Discovery with iPSC-Derived Neurons & Glia
Time: 11:00 am
day: Conference Day One Track A
Details:
• BrainXell provides a range of human iPSC-derived neurons
and glia from healthy and disease lines for use in drug
discovery applications
• Differentiating ALS patient lines harboring mutations in
disease-relevant genes (i.e. C9ORF72, SOD1, TDP-43) into
various cells of the CNS and generating isogenic controls
• Disease modeling with mono-, co-, and triculture systems
to advance personalized medicine for ALS and other neurodegenerative diseases